Stockreport

NovaBridge's Givastomig Could Drive A Major Re-Rating [Seeking Alpha]

NovaBridge Biosciences - American Depositary Shares  (NBP) 
PDF NBP's lead asset, Givastomig, has shown strong Phase 1b data—75% response rate, 16.9-month PFS, and manageable safety in gastric cancer. Upcoming 2026 Phase 1b data f [Read more]